# EDGAR Filing Document

**Accession Number:** 0001446847
**File Stem:** 0001104659-26-075730
**Filing Date:** 2026-6
**Character Count:** 8767
**Document Hash:** d5a3cf08f4a339d782273cd35eeffed6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-075730.hdr.sgml**: 20260618

**ACCESSION NUMBER**: 0001104659-26-075730

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260616

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260618

**DATE AS OF CHANGE**: 20260618

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IRONWOOD PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0001446847
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 043404176
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34620
- **FILM NUMBER:** 261102720

**BUSINESS ADDRESS:**
- **STREET 1:** 100 SUMMER STREET, SUITE 2300
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110
- **BUSINESS PHONE:** 617-621-7722

**MAIL ADDRESS:**
- **STREET 1:** 100 SUMMER STREET, SUITE 2300
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**Current Report Pursuant to**

**Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported):

June 16, 2026

**IRONWOOD PHARMACEUTICALS, INC.**

*(Exact name of registrant as specified in its charter)*

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-34620** | **04-3404176** |
| *(State or other jurisdiction* | *(Commission File Number)* | *(I.R.S. Employer* |
| *of incorporation)* |  | *Identification Number)* |

---

---

| | |
|:---|:---|
| **100 Summer Street** **, Suite 2300** |  |
| **Boston** **, Massachusetts** | **02110** |
| *(Address of principal* | *(Zip code)* |
| *executive offices)* |  |

---

**(617) 621-7722**

*(Registrant's telephone number,*

*including area code)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which<br> registered |
| Class A common stock, $0.001 par value | IRWD | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On June 16, 2026, Ironwood Pharmaceuticals, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). As described in Item 5.07 below, at the Annual Meeting, the stockholders of the Company voted to approve an amendment (the "Plan Amendment") to the Company's Amended and Restated 2019 Equity Incentive Plan (the "Plan", as amended by the Plan Amendment, the "Amended Plan"). The Plan Amendment, which had previously been adopted by the Company's Board of Directors (the "Board") subject to stockholder approval, increases the number of shares of Company's Class A common stock available for issuance under the Amended Plan by 10,000,000 shares.

The terms of the Amended Plan are described on pages 53 to 58 in the Company's [Definitive Proxy Statement on Schedule 14A , filed with the Securities and Exchange Commission on April 28, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/1446847/000110465926050325/tm261380-1_def14a.htm) (the "Proxy Statement").

The foregoing description of the Plan Amendment is a summary only and is qualified in its entirety by reference to the full text of the Plan Amendment, a copy of which is attached as Exhibit 10.1 hereto.

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

The final voting results for the Annual Meeting are as follows:

1. The stockholders elected eight director nominees, each to serve on the board of directors of the Company for a one-year term extending
until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death,
resignation or removal, based on the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Director Nominee** | **For** | **Withheld** | **Broker Non-Votes** |
| Mark Currie, Ph.D. | 107222711 | 2414993 | 15446984 |
| Alexander Denner, Ph.D. | 104323731 | 5313973 | 15446984 |
| Jon Duane | 105956515 | 3681189 | 15446984 |
| Marla Kessler | 107142336 | 2495368 | 15446984 |
| Thomas McCourt | 107152086 | 2485618 | 15446984 |
| Julie McHugh | 104403033 | 5234671 | 15446984 |
| Catherine Moukheibir | 106410985 | 3226719 | 15446984 |
| Jay Shepard | 107209046 | 2428658 | 15446984 |

---

2. The stockholders approved, on a non-binding advisory basis, the compensation paid to the Company's named executive officers,
as disclosed in the Proxy Statement for the Annual Meeting, based on the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| &nbsp;&nbsp;104,461,936 | &nbsp;&nbsp;4,958,394 | &nbsp;&nbsp;217,374 | &nbsp;&nbsp;15,446,984 |

---

3. The stockholders approved the Plan Amendment, based on the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| &nbsp;&nbsp;104,066,785 | &nbsp;&nbsp;5,404,112 | &nbsp;&nbsp;166,807 | &nbsp;&nbsp;15,446,984 |

---

4. The stockholders ratified the selection of KPMG LLP as the Company's independent registered public
accounting firm for 2026, based on the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| &nbsp;&nbsp;121,957,895 | &nbsp;&nbsp;2,783,154 | &nbsp;&nbsp;343,639 | &nbsp;&nbsp;- |

---

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

---

| | |
|:---|:---|
| Exhibit No. | Description |
| [10.1](tm2618313d1_ex10-1.htm) | [Amendment No. 1 to the Amended and Restated 2019 Equity Incentive Plan.](tm2618313d1_ex10-1.htm) |
| 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Ironwood Pharmaceuticals, Inc.** | **Ironwood Pharmaceuticals, Inc.** |
| Dated: June 18, 2026 | By: | /s/ Ronald Silver |
|  |  | Name: Ronald Silver |
|  |  | Title: Interim Chief Financial Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**IRONWOOD PHARMACEUTICALS, INC.**

**AMENDMENT NO. 1 TO AMENDED AND RESTATED 2019 EQUITY INCENTIVE PLAN**

This Amendment No. 1 (this "Amendment") is made to the Amended and Restated 2019 Equity Incentive Plan (the "Plan") of Ironwood Pharmaceuticals, Inc. (the "Company").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The reference to "16,000,000 shares" in the first sentence of Section 4(a) of the Plan is replaced in its entirety with "26,000,000 shares".

Except as set forth above, all other terms of the Plan shall remain unchanged and in full force and effect. Capitalized terms used herein and not otherwise defined herein shall have the respective meanings assigned to them in the Plan.

This Amendment was adopted by the Board of Directors of the Company on March 10, 2026 and was approved by the stockholders of the Company on June 16, 2026.